Does the media refer more to TWST or DNA?

In the previous week, Twist Bioscience had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Twist Bioscience and 1 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.63 beat Ginkgo Bioworks' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or DNA?

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Aurinia Pharmaceuticals and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.00 beat Aurinia Pharmaceuticals' score of -0.02 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RAPP or DNA?

In the previous week, Rapport Therapeutics had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Rapport Therapeutics and 1 mentions for Ginkgo Bioworks. Rapport Therapeutics' average media sentiment score of 0.85 beat Ginkgo Bioworks' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DNA or SNDX?

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Syndax Pharmaceuticals and 1 mentions for Ginkgo Bioworks. Syndax Pharmaceuticals' average media sentiment score of 1.61 beat Ginkgo Bioworks' score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to DNA or NUVB?

In the previous week, Nuvation Bio had 13 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 14 mentions for Nuvation Bio and 1 mentions for Ginkgo Bioworks. Nuvation Bio's average media sentiment score of 0.52 beat Ginkgo Bioworks' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Ginkgo Bioworks (DNA) Competitors

$7.36 -0.57 (-7.18%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$7.43 +0.07 (+0.94%)

As of 07/24/2026 07:34 PM Eastern

Compare

DNA vs. TWST, AUPH, RAPP, SNDX, and NUVB

Should you buy Ginkgo Bioworks stock or one of its competitors? MarketBeat compares Ginkgo Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ginkgo Bioworks include Twist Bioscience (TWST), Aurinia Pharmaceuticals (AUPH), Rapport Therapeutics (RAPP), Syndax Pharmaceuticals (SNDX), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$409.48M	13.73	-$77.67M	-$1.33	N/A
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A

Twist Bioscience presently has a consensus target price of $90.30, indicating a potential upside of 0.03%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential upside of 15.47%. Given Ginkgo Bioworks' higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Twist Bioscience has a net margin of -19.85% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -26.73% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Twist Bioscience has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

In the previous week, Twist Bioscience had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Twist Bioscience and 1 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.63 beat Ginkgo Bioworks' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus target price of $17.25, indicating a potential upside of 12.38%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential upside of 15.47%. Given Ginkgo Bioworks' higher probable upside, analysts clearly believe Ginkgo Bioworks is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Ginkgo Bioworks' net margin of -215.41%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Aurinia Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	6.97	$287.20M	$2.17	7.07
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Aurinia Pharmaceuticals and 1 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.00 beat Aurinia Pharmaceuticals' score of -0.02 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aurinia Pharmaceuticals beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Rapport Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Rapport Therapeutics' return on equity of -24.78% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Rapport Therapeutics currently has a consensus price target of $57.86, indicating a potential upside of 42.23%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential upside of 15.47%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Rapport Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rapport Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

In the previous week, Rapport Therapeutics had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Rapport Therapeutics and 1 mentions for Ginkgo Bioworks. Rapport Therapeutics' average media sentiment score of 0.85 beat Ginkgo Bioworks' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rapport Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	$20M	97.28	-$111.48M	-$2.60	N/A
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A

Summary

Rapport Therapeutics beats Ginkgo Bioworks on 12 of the 17 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Syndax Pharmaceuticals?

Ginkgo Bioworks (NYSE:DNA) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Syndax Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A
Syndax Pharmaceuticals	$172.35M	10.70	-$285.42M	-$2.79	N/A

Syndax Pharmaceuticals has a net margin of -111.88% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 2 mentions for Syndax Pharmaceuticals and 1 mentions for Ginkgo Bioworks. Syndax Pharmaceuticals' average media sentiment score of 1.61 beat Ginkgo Bioworks' score of 0.00 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential upside of 15.47%. Syndax Pharmaceuticals has a consensus price target of $42.55, suggesting a potential upside of 104.45%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Syndax Pharmaceuticals beats Ginkgo Bioworks on 11 of the 17 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Nuvation Bio?

Ginkgo Bioworks (NYSE:DNA) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Nuvation Bio has a net margin of -102.06% compared to Ginkgo Bioworks' net margin of -215.41%. Nuvation Bio's return on equity of -44.10% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Ginkgo Bioworks presently has a consensus price target of $8.50, indicating a potential upside of 15.47%. Nuvation Bio has a consensus price target of $12.38, indicating a potential upside of 92.01%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Nuvation Bio had 13 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 14 mentions for Nuvation Bio and 1 mentions for Ginkgo Bioworks. Nuvation Bio's average media sentiment score of 0.52 beat Ginkgo Bioworks' score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has lower revenue, but higher earnings than Ginkgo Bioworks. Nuvation Bio is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$151.40M	3.18	-$312.76M	-$5.36	N/A
Nuvation Bio	$143.05M	15.69	-$204.63M	-$0.43	N/A

Summary

Nuvation Bio beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$480.79M	$3.67B	$6.87B	$23.47B
Dividend Yield	N/A	2.19%	2.67%	4.20%
P/E Ratio	-1.37	21.48	27.14	30.75
Price / Sales	3.18	170.08	517.06	166.31
Price / Cash	N/A	157.90	50.54	31.69
Price / Book	0.84	7.88	10.28	4.73
Net Income	-$312.76M	$23.86M	$3.60B	$1.07B
7 Day Performance	-6.63%	-3.82%	-1.27%	-0.45%
1 Month Performance	-22.82%	-2.61%	-0.37%	0.72%
1 Year Performance	-47.25%	32.79%	18.30%	14.09%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	1.3094 of 5 stars	$7.36 -7.2%	$8.50 +15.5%	-50.6%	$480.79M	$151.40M	N/A	640
TWST Twist Bioscience	1.5488 of 5 stars	$87.45 -6.8%	$90.30 +3.3%	+157.3%	$5.84B	$376.57M	N/A	990	Positive News
AUPH Aurinia Pharmaceuticals	2.6896 of 5 stars	$15.25 -4.4%	$17.25 +13.1%	+69.2%	$2.05B	$283.05M	7.03	300	News Coverage Upcoming Earnings Analyst Downgrade
RAPP Rapport Therapeutics	2.5108 of 5 stars	$40.21 -5.7%	$57.86 +43.9%	+144.8%	$2.04B	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	3.1052 of 5 stars	$22.29 -2.2%	$42.55 +90.9%	+108.3%	$2.02B	$172.35M	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, AUPH, RAPP, SNDX, and NUVB

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Summary

How does Ginkgo Bioworks compare to Rapport Therapeutics?

Summary

How does Ginkgo Bioworks compare to Syndax Pharmaceuticals?

Summary

How does Ginkgo Bioworks compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, AUPH, RAPP, SNDX, and NUVB

How does Ginkgo Bioworks compare to Twist Bioscience?

Do insiders & institutionals have more ownership in TWST or DNA?

Which has higher earnings & valuation, TWST or DNA?

Do analysts recommend TWST or DNA?

Is TWST or DNA more profitable?

Which has more risk and volatility, TWST or DNA?

Does the media refer more to TWST or DNA?

Summary

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Which has more volatility & risk, AUPH or DNA?

Do analysts rate AUPH or DNA?

Is AUPH or DNA more profitable?

Which has higher earnings and valuation, AUPH or DNA?

Does the media favor AUPH or DNA?

Do insiders and institutionals have more ownership in AUPH or DNA?

Summary

How does Ginkgo Bioworks compare to Rapport Therapeutics?

Is RAPP or DNA more profitable?

Do analysts prefer RAPP or DNA?

Do insiders and institutionals have more ownership in RAPP or DNA?

Which has more risk and volatility, RAPP or DNA?

Does the media refer more to RAPP or DNA?

Which has preferable earnings and valuation, RAPP or DNA?

Summary

How does Ginkgo Bioworks compare to Syndax Pharmaceuticals?

Which has better earnings and valuation, DNA or SNDX?

Is DNA or SNDX more profitable?

Which has more risk and volatility, DNA or SNDX?

Do institutionals & insiders believe in DNA or SNDX?

Does the media prefer DNA or SNDX?

Do analysts rate DNA or SNDX?

Summary

How does Ginkgo Bioworks compare to Nuvation Bio?

Do institutionals and insiders have more ownership in DNA or NUVB?

Which has more volatility and risk, DNA or NUVB?

Is DNA or NUVB more profitable?

Do analysts rate DNA or NUVB?

Does the media refer more to DNA or NUVB?

Which has preferable valuation and earnings, DNA or NUVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools